Literature DB >> 21354385

Mechanisms of hepatitis C virus-related insulin resistance.

Francesco Negro1.   

Abstract

The hepatitis C virus (HCV) infection has been shown to have direct and/or indirect effects on glucose metabolism, leading to insulin resistance and, in predisposed individuals, type 2 diabetes. This is supported by several experimental, clinical and epidemiological data. The detailed molecular events leading to insulin resistance in HCV-infected patients are unclear. HCV infects primarily the liver and, to a very minor extent, mononuclear cells. Direct interactions between HCV products and the hepatocyte insulin signaling pathway have been reported by several authors. However, recent evidence supports the existence of a significant extrahepatic component of HCV-induced insulin resistance. Thus, the molecular pathogenesis of glucose metabolism disturbances observed in hepatitis C is much more complex than expected. The clinical management of such condition remains empirical.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21354385     DOI: 10.1016/j.clinre.2011.01.011

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  9 in total

Review 1.  Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Dilia Giuggioli; Andrea Di Domenicantonio; Ilaria Ruffilli; Alda Corrado; Silvia Fabiani; Santino Marchi; Clodoveo Ferri; Ele Ferrannini; Poupak Fallahi
Journal:  World J Diabetes       Date:  2014-10-15

2.  Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice.

Authors:  Hervé Lerat; Mohamed Rabah Imache; Jacqueline Polyte; Aurore Gaudin; Marion Mercey; Flora Donati; Camille Baudesson; Martin R Higgs; Alexandre Picard; Christophe Magnan; Fabienne Foufelle; Jean-Michel Pawlotsky
Journal:  J Biol Chem       Date:  2017-05-30       Impact factor: 5.157

3.  Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders.

Authors:  Ikuo Shoji; Lin Deng; Hak Hotta
Journal:  Front Microbiol       Date:  2012-01-10       Impact factor: 5.640

4.  Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation.

Authors:  Esther Rey; Javier Ampuero; Francisca Molina-Jiménez; Patricia Marañón; Yaiza García-García; Rocío Múñoz-Hernández; Manuel Romero-Gómez; Carmelo García-Monzón; Pedro Majano; Águeda González-Rodríguez
Journal:  Clin Transl Med       Date:  2021-01

5.  Hepatitis C virus infection suppresses GLUT2 gene expression via downregulation of hepatocyte nuclear factor 1α.

Authors:  Chieko Matsui; Ikuo Shoji; Shusaku Kaneda; Imelda Rosalyn Sianipar; Lin Deng; Hak Hotta
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

6.  Hepatitis C Virus NS5A Protein Promotes the Lysosomal Degradation of Hepatocyte Nuclear Factor 1α via Chaperone-Mediated Autophagy.

Authors:  Chieko Matsui; Lin Deng; Nanae Minami; Takayuki Abe; Kazuhiko Koike; Ikuo Shoji
Journal:  J Virol       Date:  2018-06-13       Impact factor: 5.103

7.  Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture.

Authors:  Feyza Gunduz; Fatma M Aboulnasr; Partha K Chandra; Sidhartha Hazari; Bret Poat; Darren P Baker; Luis A Balart; Srikanta Dash
Journal:  Virol J       Date:  2012-08-03       Impact factor: 4.099

8.  Clinical efficacy of free androgen index, a surrogate hallmark of circulating free testosterone level, in male patients with HCV-related chronic liver disease.

Authors:  Takashi Himoto; Koji Fujita; Teppei Sakamoto; Takako Nomura; Asahiro Morishita; Hirohito Yoneyama; Reiji Haba; Tsutomu Masaki
Journal:  J Clin Biochem Nutr       Date:  2018-06-08       Impact factor: 3.114

Review 9.  Current Trends of Essential Trace Elements in Patients with Chronic Liver Diseases.

Authors:  Takashi Himoto; Tsutomu Masaki
Journal:  Nutrients       Date:  2020-07-14       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.